Purpose: Anderson-Fabry disease is an inherited lysosomal storage disease with a broad and unspecific range of symptoms, a painful course of disease and early death. The recent development of new enzyme therapy emphasises the need for early diagnosis and treatment of undiagnosed patients. One of the affected organs of Anderson-Fabry disease is the eye. Cornea verticillata – corneal opacities and corneal dystrophy – as well as tortuositas vasorum can occur in an early stage of the disease affecting almost all hemizygous men and more than 70% of heterozygous women. In order to identify unknown cases with Anderson-Fabry disease, we carried out a screening programme contacting Austrian ophthalmologists. Methods: All 658 Austrian ophthalmologists were asked to record patients with cornea verticillata as well as tortuositas vasorum – twice at an interval of 3 months. Results: 33% of the contacted ophthalmologists replied, identifying 5 patients suspected of having Anderson-Fabry disease. After additional examinations including tests for enzyme activities Anderson-Fabry disease was confirmed in 1 man. Conclusion: We have identified 1 case with Anderson-Fabry disease through our ophthalmology screening programme among a population of approximately of 8 million. Ophthalmologic screening programmes for ocular manifestations typical of Anderson-Fabry disease are limited because of the moderate visual affection in these patients. Nevertheless, considering the limited options to detect such cases otherwise, ophthalmologists have a major responsibility to identify patients with Anderson-Fabry disease on routine examinations.

Keywords:
Anderson-Fabry disease, Cornea verticillata, Tortuositas vasorum, Ophthalmologic screening programme
1.
Schiffmann R, Kopp JB, Austin HA 3rd, et al: Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 2001;285:2743–2749.
2.
Kolodny EH, Pastores GM: Anderson-Fabry disease: Extrarenal, neurologic manifestations. J Am Soc Nephrol 2002;13(suppl 2):S150–S153.
3.
Pastores GM, Thadhani R: Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 2001;358:601–603.
4.
MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750–760.
5.
MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769–775.
6.
Kampmann Ch, Baehner F, Ries M, et al: Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol 2002;13(suppl 2):S147–S149.
7.
Franceschetti AT: Fabry disease: Ocular manifestations. Birth Defects Original Article Ser 1976;12:195–208.
8.
Sher NA, Letson RD, Desnick RJ: The ocular manifestations in Fabry disease. Arch Ophthalmol 1979;97:671–676.
9.
Desnick RJ, Ioannou YA, Eng CM: α-Galactosidase A deficiency: Fabry disease; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York, McGraw Hill, 2001, vol 3, pp 3733–3774.
10.
Peters FPJ, Vermeulen A, Kho TL: Anderson-Fabry’s disease: Galactosidase deficiency. Lancet 2001;357:138–140.
11.
Levy M, Feingold J: Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000;58:925–943.
12.
Meikle PJ, Hopwood JJ, Clague AE, et al: Prevalence of lysosomal storage disorders. JAMA 1999;281:249–254.
13.
Morgan SH, Crawfurd MA: Anderson-Fabry disease. BMJ 1988;297:872–873.
14.
Nakao S, Takenaka T, Maeda M, et al: An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288–293.
15.
Beer G, Reinecke P, Gabbert HE, et al: Fabry disease in patients with hypertrophic cardiomyopathy. Z Kardiol 2002;91:992–1002.
16.
Brady RO: Ophthalmologic aspects of lipid storage diseases. Ophthalmology 1978;85:1007–1013.
17.
Lorenz M, Hauser AC, Püspök-Schwarz M, et al: Anderson-Fabry disease in Austria. Wien Klin Wochenschr 2003;115:235–240.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.